18 March 2024
MYCELX Technologies Corporation
("MYCELX" or the "Company") (AIM: MYX)
Grant of Share Options to Chief Financial Officer
On 15 March 2024 Ms. Slayton, a PDMR of the Company, was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):
| Name of PDMR | Number of share options granted | Exercise price | Total number of share options held following this notification | Total number of share options as % of current issued share capital |
| | | | | |
| Kimberly Slayton | 50,000 | US$0.59 | 313,334 | 1.36% |
Ms. Slayton holds no Common Shares in the issued capital of the Company.
The share options granted to Kimberly Slayton on 15 March 2024 will vest as to 50% on 31 December 2024 and 50% on 31 December 2025. The exercise price was based on the mid-market closing price of the Company's Common Shares at 15 March 2024, and the closing US/£ exchange rate at that date.
The above grant is included as part of wider grants of 300,000 options in aggregate to employees across the Company on 13 March 2024 and 15 March 2024, representing 1.31% of the current issued share capital. All of the options must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.
Details of the transaction are reported in the PDMR notification below:
| 1 | Details of the person discharging managerial responsibilities / person closely associated
| ||
| a) | Name | Kimberly Slayton | |
| 2 | Reason for the notification
| ||
| a) | Position/status | Chief Financial Officer
| |
| b) | Initial notification/Amendment | Initial Notification
| |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MYCELX Technologies Corporation
| |
| b) | LEI | 213800UJZINIK2VD1G48 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
| a) | Description of the financial instrument, type of instrument | Grant of options over 50,000 common shares of US$0.025 each.
ISIN: US62847T2024
| |
| c) | Currency | US$ | |
| d) | Price(s) and volumes(s) | Price(s) | Volume(s)
|
| | | US$0.59 | 50,000 |
| e) | Aggregated information - Aggregated volume - Price
| As above | |
| f) | Date of the transaction | 15 March 2024 | |
| g) | Place of the transaction | NA (grant of options) | |
For further information, please contact:
| MYCELX Technologies Corporation Connie Mixon, CEO Kim Slayton, CFO
|
Tel: +1 888 306 6843 |
| Canaccord Genuity Limited (Nomad and Sole Broker) Henry Fitzgerald-O'Connor Ana Ercegovic
|
Tel: +44 20 7523 8000 |
| Celicourt Communications (Financial PR) Mark Antelme Jimmy Lea Charlie Denley-Myerson |
Tel: +44 20 7770 6424 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
